Role of the MMP9 gene in hemorrhagic transformations after tissue-type plasminogen activator treatment in stroke patients

Stroke. 2012 May;43(5):1398-400. doi: 10.1161/STROKEAHA.111.639823. Epub 2012 Apr 10.


Background and purpose: Despite the benefits of tissue-type plasminogen activator treatment, some stroke patients experience adverse hemorrhagic transformations (HT). Plasma protein levels of MMP9 have been associated with HT occurrence. We aimed to analyze the association of the MMP9 gene with HT occurrence.

Methods: We analyzed the MMP9 gene in blood samples from 885 stroke patients treated with tissue-type plasminogen activator by tag-SNP, imputed SNP, direct sequencing, and RNA expression.

Results: We did not observe any significant association between MMP9 genetic variations or MMP9 expression and HT occurrence. Moreover, no association was found between MMP9 expression and MMP9 polymorphisms.

Conclusions: Genetic variations in the MMP9 gene are not associated with HT occurrence in tissue-type plasminogen activator-treated patients.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cerebral Hemorrhage / blood
  • Cerebral Hemorrhage / epidemiology*
  • Cerebral Hemorrhage / genetics*
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Follow-Up Studies
  • Genetic Predisposition to Disease / genetics
  • Humans
  • Incidence
  • Male
  • Matrix Metalloproteinase 9 / blood
  • Matrix Metalloproteinase 9 / genetics*
  • Middle Aged
  • Polymorphism, Single Nucleotide / genetics
  • RNA, Messenger / blood
  • Retrospective Studies
  • Stroke / blood
  • Stroke / drug therapy*
  • Tissue Plasminogen Activator / therapeutic use*
  • Treatment Outcome


  • Fibrinolytic Agents
  • RNA, Messenger
  • Tissue Plasminogen Activator
  • Matrix Metalloproteinase 9